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Purpose: The beneficial effect of a high dose of statin (HDS) compared
with lower doses is controversial in secondary prevention. We studied factors
impacting the prescription of a HDS at discharge after an Acute Myocardial
Infarction [AMI], and assessed effects of this HDS on mortality and cardio-
vascular morbidity.
Methods: Participants were 2240 survivors of a STEMI or NSTEMI from
the French FAST-MI registry conducted in 2005, with a known statin dose at
discharge. Rosuvastatin at any dose, atorvastatin ≥20 mg/d and Simvastatin
40 mg/d were considered as HDS. Factors related to HDS prescription were
studied using logistic regression. Impact of HDS prescription on occurrence of
death or major cardiovascular events [MACE] (MI, stroke or revascularisa-
tion) was studied using a Cox proportional hazards model after propensity
score matching.
Results: 54.5% of the patients had a HDS prescription at discharge. In
crude risk analyses, HDS prescription was associated with a lower risk of
death or MACE (HR=0.84 [0.71-0.98], p<0.03). However, patients already
under treatment with a HDS before the ACS, patients managed in a university
hospital, located in a large city, with a younger age, a STEMI, a high blood
pressure at entry (≥140 mmHg) and who were discharged rapidly after their
AMI were more likely to benefit from a HDS prescription at discharge. After
propensity score matching, the dose of statin the patients received at discharge
was not related to death or MACE occurrence in the following 3 years
(HR=1.04 [0.77-1.36], p=0.87). Using a more stringent definition for HDS
(atorvastatin ≥40 mg or rosuvastatin ≥20 mg) yielded similar results.
Conclusions: The issue of long term benefit of HDS therapy compared
with lower ones after an AMI remains unanswered in an observational
context, because in this “real life” large registry, high doses were preferen-
tially prescribed to patients with a low risk profile, but less commonly to
patients with a high risk profile.
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Guidelines recommend lowering LDL-cholesterol (LDL-c) according to
level of cardiovascular risk. We aimed at exploring, in the French general
population, the proportion of subjects above the recommended goal, and to
assess among these people, how much LDL-c should be further decreased to
reach the goal.
Methods: We analyzed data from a multicenter cross-sectional study
conducted in 2006-2007 in Lille, Strasbourg and Toulouse areas. Participants
were selected from the general population by drawing on polling lists.
Results: The sample comprised 4609 subjects aged 35-74 (49.9% of women),
among whom 35.0% had no cardiovascular risk factor (age < 50 for men, 60 for
women; no family history of premature coronary heart disease; no hypertension;
no diabetes, HDL-c ≥ 0.40 g/L; and no current or recent smoking). The sample
was further composed of 27.1%, 16.5%, and 3.9% of subjects with 1, 2 and 3 risk
factors, respectively, and 17.5% of people at high cardiovascular risk.
The percentage of people not reaching LDL-c goal increased from subjects
with 0 to those with 3 risk factors (1.2%; 9.7%; 28.0%; and 56.9%), and
82.2% of high risk subjects presented with LDL-c above 1 g/L. These latter
people had either a documented cardiovascular disease (68.8% had LDL-
c ≥ 1 g/L), or an elevated 10-year absolute risk of cardiovascular disease
(86.7% ≥ 1 g/L). In high risk people above the goal, mean LDL-c was 1.49 g/L
(±0.32). An average 31.2% (±13.3) decrease in LDL-c was requested to reach
the goal. The average decrease requested for people with 0 to 3 risk factors
who were above the goal, was 9.7% (±8.6), 8.8% (±7.8), 12.6% (±9.6), and
15.1% (±10.1), respectively. A similar analysis was conducted considering
ESC instead of French guidelines.
Conclusion: By estimating the average decrease in LDL-c needed to reach
recommended goal in different risk categories, this study provides helpful
information that may guide health agencies to conceive recommendations for
management strategies.
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Background: Despite demonstrated positive effects in a number of clinical
trials, the evidence is lacking as to the impact of statins on the risk of first
myocardial infarction (MI) in real life settings.
Objectives: To assess the impact of real life statin utilization on the risk
of first non-fatal MI
Methods: Case-control methodology using the pharmacoepidemiological
information system PGRx. Data on comorbidities, risk factors and medications
were obtained from medical records and patient telephone interviews. General
practices (n=371) and cardiology centres (n=60) across France were employed
in the study. Cases were patients with the first MI ≤ 1 month before the date of
recruitment (n=2238). Controls were patients seen by a general practitioner (GP)
with no restriction as to the reasons of consultation (n=2238), matched to MI
cases on gender, age, frequency of visits to a doctor, date of recruitment and per-
sonal history of non-cardiovascular chronic disease. Statin exposure was defined
as any utilisation in the two-year prior to date of MI in cases or recruitment date
in controls. Adjusted odds ratios (OR) of the risk of first MI was estimated by
multiple conditional logistic regression models. Comparative effectiveness and
propensity to use of individual statin molecules were assessed.
Results: The use of statins was associated with a lower MI risk (adjusted
OR 0.67 [95% CI 0.56 – 0.79] for current use (within 2 months before the
index date) and 0.73 [0.62 0.86] for any use within 24 months). Among indi-
vidual statins, rosuvastatin was associated with the lowest MI risk (adjusted
OR 0.49 [0.35 – 0.68] for any use in 24 months preceding the index date) fol-
lowed by simvastatin (0.62 [0.46 – 0.84]).
Conclusions: In this first major population-based observational study we
reproduced the results observed in recent meta-analyses accounting for real
life compliance and population variability. The results could be of interest and
applicable to other industrialised countries as the observed risk reduction was
constant across MI risk levels.
